Chester County News and Community Website
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently announced presentation of data from …
Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, this week announced positive topline results from its Phase …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced the release of the abstract containing interim data from the first 19 patients in its pilot Phase 1/2 clinical trial designed …
Read More
The U.S. Food and Drug Administration recently announced that it has awarded six new clinical trial research grants to principal investigators from academia and industry totaling over $16 million over …
Read More
BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced dosing of the first …
Read More
As part of its ongoing efforts to fight COVID-19, the U.S. Food and Drug Administration broadened the scope of the existing emergency use authorization (EUA) for the drug Veklury (remdesivir) to …
Read More
WASHINGTON, D.C. — The Department of Veterans Affairs (VA) recently announced a new clinical trial to study convalescent plasma for treating seriously ill COVID-19 patients as part of a larger effort …
Read More
The U.S. Food and Drug Administration this week issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the …
Read More
WEST READING, PA — Tower Health has recently enrolled 36 COVID-19 patients in the “IMmunoPhenotyping Assessment in a COVID-19 Cohort” study, or IMPACC, that aims to develop effective treatments for …
Read More MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) recently provided an update on corporate activities and reported second-quarter 2020 financial results.
Read More